Partner Peter Damerell comments in Life Sciences Intellectual Property Review about the UK Supreme Court judgement in Actavis v Eli Lilly. The article can be read here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
